Trial Profile
A pilot study of the safety and efficacy of ALX-0600 in subjects with moderately active Crohn's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Teduglutide (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors NPS Pharmaceuticals
- 12 Nov 2015 Status changed from active, no longer recruiting to completed as per NCT.
- 22 Sep 2009 New trial record.